)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Huadong Medicine Co
Huadong Medicine Co (000963) investor relations material
Huadong Medicine Co Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary28 Oct, 2026
Executive summary
9M 2026 revenue rose 1.09% YoY to ¥33.02bn; attributable net income increased 0.87% to ¥2.77bn, while adjusted net income grew 3.57% to ¥2.79bn.
Q3 revenue declined 0.33% YoY to ¥10.95bn and attributable net income fell 2.35% to ¥911.1m; adjusted net income was nearly flat, up 0.03%.
Innovation products and services gained traction, while medical aesthetics remained under pressure from market adjustment and intensifying competition.
Financial highlights
9M revenue was ¥33.019bn (+1.09% YoY); attributable net income was ¥2.772bn (+0.87%) and adjusted net income was ¥2.790bn (+3.57%).
Q3 revenue was ¥10.952bn (-0.33% YoY); attributable net income was ¥911.1m (-2.35%) and adjusted net income was ¥932.1m (+0.03%).
9M operating cash flow was ¥1.861bn, down 28.73% YoY; consolidated net profit was ¥2.748bn versus ¥2.742bn in the prior-year period.
Outlook and guidance
Around 10 pipeline products in NDA/BLA review are expected to gain approval next year; more than 40 innovative products are expected to launch in phases over the next five years.
HDM1002 weight-management Phase III met primary and key secondary endpoints; an NDA filing in China is planned, while T2D Phase III primary-endpoint data are expected in Q4 2026.
HDM1005 weight-management Phase III reached its 40-week primary-endpoint interim analysis; pre-NDA communication is planned for Q4 2026.
Industrial microbiology is expected to sustain growth with overseas expansion; medical aesthetics plans continued strategic adjustment and organizational optimization to rebuild recovery momentum.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Huadong Medicine Co
- Stable revenue and profit growth driven by innovation, despite aesthetic medicine headwinds.000963
Q2 2026 - Revenue up 4.07% to RMB 43.61B; innovative product sales surged 64.2% year-over-year.000963Q4 2025
- Net profit rose 9.56% year-over-year to RMB 1.00 billion, led by innovative product growth.000963Q1 2026
- Q3 2025 saw 4.53% revenue growth and 7.71% net profit growth year-over-year.000963Q3 2025
- Revenue and net profit rose, driven by innovation and robust segment performance.000963Q2 2025
- Record H1 2024 profit and revenue growth, with robust R&D and strong interim dividend.000963Q2 2024
- 2023 revenue and profit hit record highs, fueled by innovation and global expansion.000963Q4 2023
- Net profit surged 23.72% to ¥3.51 billion on record revenue and robust R&D investment.000963Q4 2024
- Revenue and profit rose on strong pharma growth, while aesthetics rebounded sequentially.000963Q1 2025
Next Huadong Medicine Co earnings date
Q4 202623 Apr, 2027
Huadong Medicine Co
Next Huadong Medicine Co earnings date
Q4 202623 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Huadong Medicine Co., Ltd. is engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company’s offerings include a wide range of prescription drugs, over-the-counter medications, and healthcare products used in fields such as oncology, nephrology, endocrinology, and immunology. In addition to pharmaceuticals, Huadong Medicine operates in the medical aesthetics and biotechnology sectors. The company is headquartered in Hangzhou, China, and its shares are listed on the SZSE.